Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.verified

OTLK

Price:

$7.07

Market Cap:

$165.48M

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, In...[Read more]

Industry

Biotechnology

IPO Date

2016-06-14

Stock Exchange

NASDAQ

Ticker

OTLK

The PE Ratio as of June 2024 (TTM) for Outlook Therapeutics, Inc. (OTLK) is -0.59

According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.59. This represents a change of -74.14% compared to the average of -2.28 of the last 4 quarters.

Outlook Therapeutics, Inc. (OTLK) Historical PE Ratio (quarterly & annually)

How has OTLK PE Ratio performed in the past?

The mean historical PE Ratio of Outlook Therapeutics, Inc. over the last ten years is -24.95. The current -0.59 PE Ratio has changed 136.43% with respect to the historical average. Over the past ten years (40 quarters), OTLK's PE Ratio was at its highest in in the March 2024 quarter at -0.32. The PE Ratio was at its lowest in in the June 2020 quarter at -194.17.

Quarterly (TTM)
Annual

Average

-24.95

Median

-16.32

Minimum

-87.96

Maximum

-0.94

Outlook Therapeutics, Inc. (OTLK) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Outlook Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 320.38%

Maximum Annual PE Ratio = -0.94

Minimum Annual Increase = -90.56%

Minimum Annual PE Ratio = -87.96

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.94-76.07%
2022-3.92-37.14%
2021-6.23320.38%
2020-1.48-90.56%
2019-15.70-74.61%
2018-61.86265.09%
2017-16.94-38.24%
2016-27.441.29%
2015-27.09-69.21%

Outlook Therapeutics, Inc. (OTLK) Average PE Ratio

How has OTLK PE Ratio performed in the past?

The current PE Ratio of Outlook Therapeutics, Inc. (OTLK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-3.70

5-year avg

-5.65

10-year avg

-24.95

Outlook Therapeutics, Inc. (OTLK) PE Ratio vs. Peers

How is OTLK’s PE Ratio compared to its peers?

Outlook Therapeutics, Inc.’s PE Ratio is greater than Checkpoint Therapeutics, Inc. (-1.22), less than Mustang Bio, Inc. (-0.24), greater than Reviva Pharmaceuticals Holdings, Inc. (-0.87), less than Fortress Biotech, Inc. (-0.54), less than Kodiak Sciences Inc. (-0.59), greater than Ocuphire Pharma, Inc. (-3.32), less than Protalix BioTherapeutics, Inc. (12.16), greater than EyePoint Pharmaceuticals, Inc. (-5.83), greater than SELLAS Life Sciences Group, Inc. (-1.33), greater than Eyenovia, Inc. (-0.91), greater than Cidara Therapeutics, Inc. (-1.51), less than Fortress Biotech, Inc. (-0.54), greater than Selecta Biosciences, Inc. (-3.39), greater than X4 Pharmaceuticals, Inc. (-1.50), greater than Inozyme Pharma, Inc. (-3.52), greater than Terns Pharmaceuticals, Inc. (-6.02), greater than Day One Biopharmaceuticals, Inc. (-5.55), greater than HOOKIPA Pharma Inc. (-1.86), greater than Heron Therapeutics, Inc. (-6.39), less than Galera Therapeutics, Inc. (-0.10),

Build a custom stock screener for Outlook Therapeutics, Inc. (OTLK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Outlook Therapeutics, Inc. (OTLK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Outlook Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Outlook Therapeutics, Inc. (OTLK)?

What is the highest PE Ratio for Outlook Therapeutics, Inc. (OTLK)?

What is the 3-year average PE Ratio for Outlook Therapeutics, Inc. (OTLK)?

What is the 5-year average PE Ratio for Outlook Therapeutics, Inc. (OTLK)?

How does the current PE Ratio for Outlook Therapeutics, Inc. (OTLK) compare to its historical average?